A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, Jake Shortt, Flora Yuen, John Reynolds, Hang Quach, Craig Wallington-Beddoe, Patricia Walker, Simon Harrison, Dunn Rosanne, Andrew Spencer

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population.
Original languageEnglish
Article numberPS1383
Pages (from-to)633-634
Number of pages2
JournalHemaSphere
Volume3
Issue numberS1
DOIs
Publication statusPublished - Jun 2019
Event24th Congress of the European Hematology Association - Amsterdam, Netherlands
Duration: 13 Jun 201916 Jun 2019
Conference number: 24

Keywords

  • dexamethasone
  • lenalidomide
  • multiple myeloma
  • Antigens
  • hematotoxicity
  • thalidomide
  • abdominal pain
  • Kappa
  • Kappa Myeloma antigen (KMA)

Fingerprint

Dive into the research topics of 'A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)'. Together they form a unique fingerprint.

Cite this